Retatrutide vs tirzepatide

Tirzepatide is a prescription drug with a label, a pharmacy and years of real-world use. Retatrutide isn't approved for anything, its late-stage trials have reported results, and Lilly says it plans to file with the FDA in 2027. Tirzepatide has been FDA-approved since 2022, as Mounjaro for type 2 diabetes, and since 2023 as Zepbound for weight.

The design difference is one extra job. Tirzepatide switches on two gut-hormone receptors, called GIP and GLP-1, which together quiet appetite and steady blood sugar. Retatrutide switches on those same two and adds a third, for glucagon, a hormone that tells your body to release stored fuel and burn more energy. So the usual question isn't which one is stronger, it's whether you want the recipe that's been cooked a million times or the one the test kitchen is still finishing. Our guide to research versus approved covers what that gap means in practice.

On the scale, retatrutide's trial numbers are the bigger ones. In its earlier trial the top weekly amount averaged about 24% of body weight over 48 weeks, and Lilly's recent late-stage topline results, which the company reported but hasn't yet published in full, put it at about 28% over 80 weeks at the top amount. Tirzepatide's main trial averaged about 22.5% over 72 weeks. Those are separate studies with different lengths and different people, so it isn't a fair race. A trial that puts the two head to head is underway and expected to finish around the end of 2026, and until it reports, nobody can say how big the real gap is for any one woman.

What the extra receptor changes day to day is mostly a question trial teams are still answering. Glucagon is thought to raise how much energy your body burns, which researchers see as part of why retatrutide's weight numbers run larger and why heart rate gets watched more closely with it. Appetite and digestive effects look familiar if you've read about tirzepatide, since both ride on the same gut-hormone signals. The first weeks look alike too: a weekly injection, a small starting amount and a step up about every four weeks. What differs is how much of the picture is settled, and for tirzepatide it's a lot more.

The third difference is what's actually in your hand. Prescription tirzepatide comes in a pen made to pharmaceutical standards with the amount printed on it. A research vial of either compound is only as good as the lab report that comes with it, and research versions of both vary by source in purity and in how much is really in the vial. For retatrutide that's the only form there is, so vetting the vendor is most of the job. Our guides to reading a certificate of analysis and finding quality sources walk through it. If semaglutide is the other name on your list, our semaglutide versus tirzepatide comparison covers that pair.

Both climb slowly on purpose. The early steps are mostly about letting your stomach adjust, not about the number on the scale. Where these come from: tirzepatide's steps follow the schedule in the approved drug's prescribing information, and retatrutide's mirror how it was dosed in its own trials. The slower options and the amount people settle on are what people describe, and no label or trial sets them. The full math is on the retatrutide dosage guide and the tirzepatide dosage guide.

1. Nuage Research60 mg · $149.49 $2.49/mg
2. IDUN Peptides30 mg · $79.99 $2.67/mg
3. Next Gen Peptides30 mg · $87.00 $2.90/mg
4. Glow Aminos100 mg · $329.00 $3.29/mg
5. Iron Protocol100 mg · $329.00 $3.29/mg

1. IDUN Peptides30 mg · $49.99 $1.67/mg
2. Amino Club60 mg · $109.99 $1.83/mg
3. Double R Labs60 mg · $114.99 $1.92/mg
4. Peptide Crafters120 mg · $270.00 $2.25/mg
5. Panda Peptides60 mg · $139.99 $2.33/mg

Compare both in the app. Whichever you're pricing, compare the real per-milligram cost against the milligrams you'd actually use in a week, and look for third-party purity and identity testing on the vial. Prices on both move, so read the cards on the day you're buying rather than trusting a number you saw last month. A cheap price per milligram doesn't help if the vial holds less than the label says. Our cost comparison walks through why weekly cost and per-milligram cost point different ways.

Tirzepatide: nausea, diarrhea, vomiting and constipation are the most common, mostly right after a step up, and they usually ease over time. The label also carries cautions for gallbladder problems, pancreatitis and a rodent thyroid finding, and a rise in heart rate is listed.

Retatrutide: the same four digestive effects, and they rise with the weekly amount. In its earlier trial, resting heart rate rose in a dose-related way, peaked around week 24 and then declined. In one of Lilly's late-stage trials, the company reported that about one in five people on the top amount had dysesthesia, which means unusual skin sensations like tingling or burning. Most cases were mild. If your heart rate stays high or you feel off, this Straight Answer covers what may be behind it, and our guide to side effects covers the rest.

A clinician who says they see patients on GLP-1 medicines describes patients who source retatrutide on their own and, a couple of months in, start waking at night with a pounding heart. That's one clinician's observation from patients, not a trial result, and the same clinician (Dr. Stirrett, credentials not verified, in a YouTube video) promotes a paid program of their own. What nobody has is a long safety record for retatrutide, and vial-to-vial differences in a research product make any one person's symptoms harder to interpret. Tirzepatide has years of use and a label behind it, which is the gap that matters here. The side effects on the tirzepatide label come from people who were monitored in trials, which a research vial can't promise.

Tirzepatide has a label and a prescriber behind it. Retatrutide has neither, and any vial of either one bought online is sold for research. You knew that, it's why you're reading this and not the label.